Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 280-283 , July 2010

High dose intermittent ticarcillin–clavulanate administration in pediatric cystic fibrosis patients

  • Jeffery T. Zobell

      Affiliations

    • Pharmacy, Intermountain Primary Children's Medical Center, 100 North Mario Capecchi Drive, Salt Lake City, UT, 84113, United States
    • Intermountain Cystic Fibrosis Pediatric Center, 100 North Mario Capecchi Drive, Salt Lake City, UT, 84113, United States
    • Corresponding Author InformationCorresponding author. 100 North Mario Capecchi Drive, Salt Lake City, UT 84113, United States. Tel.: +1 801 662 2641; fax: +1 801 662 2622.
    • ,
  • Krow Ampofo

      Affiliations

    • Division of Infectious Disease, University of Utah, PO Box 581289, Salt Lake City, UT 84132, United States
    • ,
  • Jared Cash

      Affiliations

    • Pharmacy, Intermountain Primary Children's Medical Center, 100 North Mario Capecchi Drive, Salt Lake City, UT, 84113, United States
    • ,
  • Kent Korgenski

      Affiliations

    • Division of Infectious Disease, University of Utah, PO Box 581289, Salt Lake City, UT 84132, United States
    • Microbiology, Intermountain Healthcare, 100 North Mario Capecchi Drive, Salt Lake City, UT, 84113, United States
    • ,
  • Barbara A. Chatfield

      Affiliations

    • Intermountain Cystic Fibrosis Pediatric Center, 100 North Mario Capecchi Drive, Salt Lake City, UT, 84113, United States

Received 26 February 2010 ,Revised 17 April 2010 ,Accepted 20 April 2010.

References 

  1. Timentin® Approved Package labeling. GlaxoSmithKline, 2009.
  2. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Resp Crit Care Med. 2009;180:802–808
  3. Primary Children's Medical Center Microbiology Laboratory. Cumulative Antimicrobial Susceptibility Test (Antibiogram) Data Report. 2010.
  4. Crowcroft NS, Roveaux O, Monnet DI, Mertens R. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol. 1999;20(1):31–36
  5. Nadesalingam K, Conway SP, Denton M. Risk factors for acquisition of methicillin-resistant Staphylococcus aureus (MRSA) by patients with cystic fibrosis. J Cyst Fibros. 2005;4(1):49–52
  6. Moller NE, Hoiby N. Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Scand J Infect Dis Suppl. 1981;29:87–91
  7. Reed MD, Stern RC, Myers CM, Klinger JD, Yamashita TS, Blumer JL. Therapeutic evaluation of piperacillin for acute pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. Mar–Apr 1987;3(2):101–109
  8. Red Book, Thomson Healthcare; 2007 Ed.
  9. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Resp Crit Care Med. 2003;168:918–951
  10. Microbiology and Infectious Disease in Cystic Fibrosis. Cystic Fibrosis Foundation Consensus Conference. 1994; Volume V, Section I.
  11. Ervin FR, Bullock WE. Clinical and pharmacological studies of ticarcillin in gram-negative infections. Antimicrob Agents Chemother. 1976;9(1):94–101
  12. Nelson JD, Kusmiesz H, Shelton S, Woodman E. Clinical pharmacology and efficacy of ticarcillin in infants and children. Pediatrics. 1978;61:858–863
  13. Conway SP, Miller MG, Ramsden C, Littlewood JM. Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilimicin and ticarcillin. Acta Paediatr Scand. 1985;74:107–113
  14. Horrevorts AM, de Witte J, Degener JE, Dzoljic-Danilovic G, Hop WC, Driessen O, et al. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment. Chest. 1987;92:844–848
  15. Schaad UC, Desgrandchamps D, Kraemer R. Antimicrobial therapy of pseudomonas pulmonary exacerbations in cystic fibrosis. Acta Paediatr Scand. 1986;75:128–138
  16. De Groot R, Hack BD, Weber A, Chaffin D, Ramsey B, Smith AL. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin Pharmacol Ther. 1990;47:73–78
  17. Nelson Textbook of Pediatrics 18th Edition by Kliegman, Behrman, Jenson, and Stanton; 2007, Elsevier, Inc. 1119, 1182.
  18. Red book 29th edition. Report of the Committee on Infectious Diseases. The American Academy of Pediatrics; 2009;
  19. Pediatric dosage handbook. Lexi-Comp, Inc.; 2010;
  20. http://faculty.vassar.edu/lowry/utest.html.

PII: S1569-1993(10)00041-X

doi: 10.1016/j.jcf.2010.04.003

Journal of Cystic Fibrosis
Volume 9, Issue 4 , Pages 280-283 , July 2010

Article Tools